roshni
03-06-2006, 09:11 PM
Researchers Identify First Compound To Block Progression Of Alzheimer's Disease
Researchers at UC Irvine have found that a new compound not only relieves the cognitive symptoms of Alzheimer's disease, but also reduces the two types of brain (http://www.sciencedaily.com/releases/2006/03/060305093908.htm#) lesions that are hallmarks of this devastating disease, thereby blocking its progression.
In a study with genetically modified mice, a team of UCI researchers led by Frank LaFerla, professor of neurobiology and behavior, found that a compound known as AF267B, developed by paper co-author Abraham Fisher of the Israel Institute for Biological Research, reduced both plaque lesions (http://www.sciencedaily.com/releases/2006/03/060305093908.htm#) and tangles in brain regions associated with learning and memory. Although drugs exist on the market today to treat the symptoms of Alzheimer's, AF267B represents the first disease-modifying compound, meaning it appears to affect the underlying cause and reduces the two signature lesions, plaques and tangles.
The researchers report their findings in the March 2 issue of Neuron.
more: http://www.sciencedaily.com/releases/2006/03/060305093908.htm
Researchers at UC Irvine have found that a new compound not only relieves the cognitive symptoms of Alzheimer's disease, but also reduces the two types of brain (http://www.sciencedaily.com/releases/2006/03/060305093908.htm#) lesions that are hallmarks of this devastating disease, thereby blocking its progression.
In a study with genetically modified mice, a team of UCI researchers led by Frank LaFerla, professor of neurobiology and behavior, found that a compound known as AF267B, developed by paper co-author Abraham Fisher of the Israel Institute for Biological Research, reduced both plaque lesions (http://www.sciencedaily.com/releases/2006/03/060305093908.htm#) and tangles in brain regions associated with learning and memory. Although drugs exist on the market today to treat the symptoms of Alzheimer's, AF267B represents the first disease-modifying compound, meaning it appears to affect the underlying cause and reduces the two signature lesions, plaques and tangles.
The researchers report their findings in the March 2 issue of Neuron.
more: http://www.sciencedaily.com/releases/2006/03/060305093908.htm